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ABSTRACT 
Recent papers have reported an association between fatty liver disease and systemic insulin 
resistance in humans, but the causal relationship remains unclear. The liver may contribute to 
muscle insulin resistance by releasing secretory proteins, termed hepatokines. Here, we 
demonstrate that leukocyte cell-derived chemotaxin 2 (LECT2), as an energy-sensing 
hepatokine, is a link between obesity and skeletal muscle insulin resistance. Circulating 
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LECT2 positively correlated with the severity of both obesity and insulin resistance in 
humans. LECT2 expression was negatively regulated by starvation-sensing kinase adenosine 
monophosphate-activated protein kinase (AMPK) in H4IIEC hepatocytes. Genetic deletion of 
LECT2 in mice increased insulin sensitivity in the skeletal muscle. Treatment with 
recombinant LECT2 protein impaired insulin signaling via phosphorylation of JNK in C2C12 
myocytes. These results demonstrate the involvement of LECT2 in glucose metabolism, and 
suggest that LECT2 may be a therapeutic target for obesity-associated insulin resistance. 
INTRODUCTION 
Insulin resistance is a characteristic feature of people with type 2 diabetes (1) and plays a 
major role in the development of various diseases such as cardiovascular diseases (2) and 
nonalcoholic steatohepatitis (3; 4). In an insulin-resistant state, impaired insulin action 
promotes hepatic glucose production and reduces glucose uptake by peripheral tissues. 
Insulin resistance is commonly observed in obese and overweight people, suggesting a 
potential role of ectopic fat accumulation in each insulin-target tissue for mediating insulin 
resistance (5). However, the molecular mechanisms underlying insulin resistance are now 
known to be influenced by the abnormal secretion of tissue-derived factors, traditionally 
considered separate from the endocrine system, such as adipokines (6-9), myokines (10; 11), 
and hepatokines (12-14). 
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Leukocyte cell-derived chemotaxin 2 (LECT2) is a secretory protein originally identified in 
the process of screening for a novel neutrophil chemotactic protein (15). LECT2 (in humans 
encoded by the LECT2 gene) is expressed preferentially by human adult and fetal liver cells 
and is secreted into the blood stream (16). The early study using Lect2-deficient mice showed 
that LECT2 negatively regulates the homeostasis of natural killer T cells in the liver (17). 
More recently, Anson et al. reported that LECT2 exerts anti-inflammatory and 
tumor-suppressive actions in β-catenin-induced liver tumorigenesis (18). To date, however, 
the role of LECT2 in the development of obesity and insulin resistance induced by 
over-nutrition has not yet been established.  
We have previously demonstrated that overproduction of liver-derived secretory protein 
selenoprotein P (SeP) contributes to hyperglycemia in type 2 diabetes by inducing insulin 
resistance in the liver and skeletal muscle (12). SeP has emerged from comprehensive liver 
screenings for secretory proteins whose expression levels are correlated with the severity of 
insulin resistance in patients with type 2 diabetes (12; 19; 20). Based on these findings, we 
have proposed that, analogous to adipose tissue, the liver may participate in the pathology of 
type 2 diabetes and insulin resistance, through the production of secretory proteins, termed 
hepatokines (12). Recently, the other liver-secreted proteins such as fetuin-A (21), 
angiopoietin-related protein 6 (22), fibroblast growth factor 21 (23), insulin-like growth 
factors (24), and sex hormone-binding globulin (25) have been reported as hepatokines 
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involved in glucose metabolism and insulin sensitivity. However, identification of 
hepatokines involved in fat accumulation was not adequate. In the present study, we have 
identified LECT2 as a hepatokine whose expression levels were positively correlated with the 
severity of obesity in humans. Blood levels of LECT2 were also elevated in animal models 
with obesity. Lect2-deficient mice showed an increase of insulin signaling in skeletal muscle. 
Conversely, treatment with recombinant LECT2 protein impaired insulin signaling in C2C12 
myotubes. Our data demonstrate that LECT2 functions as a hepatokine that links obesity to 
insulin resistance in the skeletal muscle. 
RESEARCH DESIGN AND METHODS 
Human clinical studies. Liver samples to be analyzed by SAGE were obtained from five 
patients with type 2 diabetes and five non-diabetic subjects who underwent surgical 
procedures for malignant tumors, including gastric cancer, gall bladder cancer, and colon 
cancer. Liver samples to be subjected to DNA chip analysis were obtained from 22 patients 
with type 2 diabetes and 11 subjects with normal glucose tolerance using 
ultrasonography-guided biopsy needles. Detailed clinical information about these subjects is 
presented elsewhere (12; 19). 
Serum samples were obtained from 200 participants who went to the Public Central Hospital 
of Matto, Ishikawa, for a complete physical examination. Following an overnight fast, venous 
blood samples were taken from each patient. Serum levels of LECT2 were measured by an 
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Ab-Match ASSEMBLY Human LECT2 kit (MBL) (26; 27). 
The HOMA-IR was calculated using the following formula: HOMA-IR = [fasting insulin 
(μU/ml) x fasting plasma glucose (mmol/L)] / 22.5 (28).  All patients provided written 
informed consent for participation in this study. All experimental protocols were approved by 
the relevant ethics committees in our institution and Matto Ishikawa Central Hospital, and 
were conducted in accordance with the Declaration of Helsinki.   
Animals. Eight-week-old c57BL/6J mice were obtained from Sankyo Lab Service (Tokyo, 
Japan).  All animals were housed in a 12-h light/dark cycle and allowed free access to food 
and water. The 60% high fat diet (D12492) was purchased from Research Diets (New 
Brunswick, NJ).   
Purification of LECT2. Murine LECT2 was expressed and purified as previously described 
(29) with minor modifications. Briefly, LECT2 was stably expressed in CHO cells. The 
protein was purified from the cultured medium by ion exchange chromatography. 
Subsequently, the fractions containing LECT2 were applied to a mono S column (GE 
Healthcare) equilibrated with 50 mM sodium phosphate buffer (pH 7.5) and eluted with a 
linear gradient of 150-350 mM NaCl. 
Lect2 knockout mice. Lect2 knockout mice were produced by homologous recombination 
using genomic DNA cloned from an Sv-129 P1 library, as described previously (17). All 
experimental mice were generated from intercross between heterozygous mice, and groups 
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were divided from littermates. As female Lect2 knockout mice had inconsistent phenotypes, 
only male mice were used in all the experiments except the experiment of the starvation. 
Materials. H4IIEC and C2C12 cells were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). Human recombinant insulin was purchased from Sigma 
Aldrich (St. Louis, MO). Rabbit anti-phospho-Akt (Ser473) monoclonal antibody, rabbit 
anti-total Akt polyclonal antibody, rabbit anti-phospho-AMPK (Thr172) monoclonal antibody, 
rabbit anti- AMPKα antibody, rabbit anti-phospho-JNK (Thr183/Try185), rabbit anti-JNK, 
rabbit anti-BiP antibody, rabbit anti-phospho-eIF2α (Ser51) antibody, rabbit anti-NF-κB p65 
antibody, rabbit anti-phospho-IKKαβ (Ser176/180) antibody, rabbit anti-IKKα antibody, and 
rabbit anti-phospho-IκBα(Ser32) antibody were purchased from Cell Signaling (Danvers, 
MA). Rabbit anti-leukocyte cell-derived chemotaxin 2 polyclonal antibody (sc-99036) and 
rabbit anti-GAPDH polyclonal antibody were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  
Transient transfection experiment. C2C12 myoblasts were grown in 12-well multi-plates 
When 30-50% confluency was reached, cells were transfected with the Fugene 6 Transfection 
Reagent (Roche) with a 1 μg control or with mLect2 expression plasmid DNA per well. After 
24 h of transfection, the medium was replaced with DMEM containing 10% FBS. 24 h later, 
when the cells reached to 100% confluency, the cells were differentiated into myotubes with 
DMEM containing 2% horse serum for 24-48 h. Then, the cells were stimulated with 100 
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ng/ml human recombinant insulin for 15 min.  
siRNA transfection in C2C12 myoblasts. C2C12 myoblasts were transiently transfected 
with a total of 15 nM of siRNA duplex oligonucleotides using Lipofectamine™ RNAiMAX 
(Invitrogen), using the reverse-transfection method according to the manufacturer's 
instructions. A JNK1-specific siRNA with the following sequence was synthesized by 
Thermo Scientific: 5’- GGAAAGAACUGAUAUACAA -3’ (sense). A JNK2-specific siRNA 
with the following sequence was synthesized by Thermo Scientific: 5’- 
GGAAAGAGCUAAUUUACAA -3’ (sense). Negative control siRNA was purchased from 
Thermo Scientific. Two days after transfection, cells were pretreated with LECT2 protein, 
followed by stimulation with 100 ng/ml of human recombinant insulin for 15 min. 
RNA isolation, cDNA synthesis, and real-time PCR analysis. Total RNA was isolated from 
cells using the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma Aldrich). Total RNA 
was isolated from mouse skeletal muscle and heart using RNeasy® Fibrous Tissue Mini Kit 
(Qiagen). Total RNA was isolated from white adipose tissue using RNeasy® Lipid Tissue 
Mini Kit (Qiagen). RNA concentrations were measured by a NanoDropR ND-1000 
spectrophotometer (NanoDrop Technology). cDNA was synthesized from 100 ng of total 
RNA using a high-capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). 
Real-time PCR analysis was performed by using TaqMan® Gene Expression Assays (Applied 
Biosystems). Primer sets and TaqMan® probes were proprietary to Applied Biosystems 
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(Assays-on-Demand™ Gene Expression Products). To control for variation in the amount of 
DNA available for PCR, target gene expression in each sample was normalized relative to the 
expression of an endogenous control (18srRNA or GAPDH) (TaqMan® Control Reagent Kit; 
Applied Biosystems).   
Treatment with recombinant LECT2 protein in C2C12 myotubes. C2C12 myoblasts were 
grown in 24-well multi-plates; after 100% confluency was reached, cells were differentiated 
into myotubes by culturing in DMEM supplemented with 2% horse serum for 42 h. C2C12 
myotubes were serum-starved and incubated in DMEM for 6 h and then treated with LECT2 
recombinant protein for various times in the absence of serum. Following treatment with 
LECT2 recombinant protein, cells were stimulated with 100 ng/ml human recombinant 
insulin for 15 min.  
Western blot studies in C2C12 myotubes. After the inulin stimulation, the cells were then 
washed in ice-cold PBS, frozen in liquid nitrogen and lysed at 4°C in 1X RIPA lysis buffer 
(Upstat Biotechnology) containing Complete Mini EDTA-free cocktail tablet 
(Roche-diagnostics) and PhosSTOP Phosphatase Inhibitor Cocktail Tablets 
(Roche-diagnostics). Lysates were then centrifuged to remove insoluble material.  Samples 
were sonicated with BIORUPTOR® (Cosmo Bio, Tokyo, Japan). Whole-cell lysates were 
then separated by 5–20% SDS-PAGE gels and were transferred to polyvinylidiene (PVDF) 
fluoride membranes, using an iBlot® gel transfer system (Invitrogen). Membranes were 
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blocked in a buffer containing 50 mM Tris, 150 mM NaCl, 0.1% Tween 20, and 5% nonfat 
milk (pH 7.5) or 5% PhosphoBLOCKER™ reagent (Cell Biolabs, Inc) for 1 h at 24°C. They 
were then probed with antibodies for 16 h at 4°C. Afterward, membranes were washed in a 
buffer containing 50 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.5 and then incubated 
with anti-rabbit IgG HRP-linked antibody (Cell Signaling) for 1 h at 24°C. Protein signals 
were detected using ECL Prime Western Blotting Detection Reagent (GE Healthcare UK 
Ltd.). Densitometric analysis of blotted membranes was performed using ImageJ software 
(NIH). 
Glucose or insulin tolerance tests in mice. In preparation for glucose tolerance testing, mice 
were fasted for 12 h. After fasting, glucose was administered intraperitoneally, and blood 
glucose levels were measured at 0, 30, 60, 90 and 120 min. For insulin tolerance testing, mice 
were fasted for 4 h. After fasting, insulin was administered intraperitoneally, and blood 
glucose levels were measured. Blood glucose levels were determined by the glucose-oxidase 
method using Glucocard (Aventis Pharma, Tokyo, Japan). The measurable levels of blood 
glucose by Glucocard range from 20 to 600 mg/dl. Because HFD-fed mice are much insulin 
resistant compared with standard diet-fed mice, lower doses of glucose were injected in 
glucose tolerance testing, as indicated in the figure legend, to avoid the elevation of blood 
glucose levels to more than 600 mg/dl. Additionally, more doses of insulin were injected to 
HFD-fed mice in insulin tolerance testing, as indicated in the figure legend, to decrease blood 
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glucose levels sufficiently. 
Western blot studies in mice. After 12 h fasting, mice were anesthetized by intraperitoneal 
administration of sodium pentobarbital. Then, insulin (1 units/kg body weight) or PBS 
(vehicle) was injected through vena cava. 10 minutes later, hind limb muscles, liver and 
epididymal white adipose tissue were removed and immediately frozen in liquid nitrogen. 
Tissue samples were homogenized using a Polytron homogenizer running at half-maximal 
speed (15,000 rpm) for 1 min on ice in 1 mL of 1X RIPA lysis buffer (Upstat Biotechnology) 
containing a Complete Mini EDTA-free cocktail tablet (Roche-diagnostics) and PhosSTOP 
Phosphatase Inhibitor Cocktail Tablets (Roche-diagnostics). Tissue lysates were solubilized 
by continuous stirring for 1 h at 4°C and centrifuged for 15 min at 14,000 rpm. Protein 
samples were separated by 5–20% SDS-PAGE gels and were transferred to PVDF 
membranes. Serine and tyrosine phosphorylation of specific target proteins was analyzed by 
Western blotting.   
Hyperinsulinemic–euglycemic clamp studies in mice. Clamp studies were performed, as 
described previously (12; 30), with slight modifications. Briefly, 2 days before the study, an 
infusion catheter was inserted into the right jugular vein of 13-week-old male C57BL6J wild 
type and Lect2-deficient mice under general anesthesia induced using sodium pentobarbital.  
Before insulin infusion, mice were fasted for 6 h. Clamp studies were performed on 
conscious and unrestrained animals. Insulin (Novolin R; Novo Nordisk, Denmark) was 
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continuously infused at a rate of 5.0 mU/kg/min, and the blood glucose concentration 
(monitored every 5 min) was maintained at 100 mg/dl through the administration of glucose 
(50%, enriched to approximately 20% with [6,6-2H2]glucose; Sigma) for 120 min. Blood 
was sampled through tail-tip bleeds at 0, 90, 105, and 120 min for the purpose of determining 
the rate of glucose disappearance (Rd). Rd values were calculated according to 
non-steady-state equations, and endogenous glucose production (EGP) was calculated as the 
difference between the Rd and the exogenous glucose infusion rates (GIR) (30). 
Exercise tolerance test in mice. Ten-week-old male C57BL 6/J wild type and 
Lect2-deficient mice were set in a running machine. After 5 min warming up running and 5 
min rest, mice started running at 11.2 m/min on 0% incline. Running speed was increased 
every 5 min till the mice reached exhaustion, defined as when the mouse stopped running for 
10 seconds on the electric tubes. 
Acute exercise experiment in mice. Eight week-old male C57BL 6/J mice were randomly 
divided into 2 groups, the exercise group and the rest group. All the mice in each group were 
warm up for 10 min at 12.6 m/min on 5% incline. After 3 hours fasting, blood was sampled 
through tail-tip bleeds. Mice in the exercise group were set in a running machine and started 
running at 12.6 m/min on 5% incline. Mice were allowed to have a 5 min rest for every 30 
min running. Meanwhile, the mice in the rest group were continually fasted. After 3 hours 
running or resting, blood was sampled again through tail-tip bleeds. Then, the mice were 
12 
anesthetized and sacrificed to allow isolation of the liver tissue. 
Starvation experiment in mice. 20 weeks old female C57BL 6/J wild type and 
Lect2-deficient mice were starved for totally 60 hours with water supplied. Body weight was 
measured and blood was sampled through tail-tip bleeds at 12hour, 24hour and 36 hour after 
starvation. 60 hours later, mice were injected with insulin intraperitoneally at the 
concentration of 10 units/kg body weight. Fifteen minutes later, mice were anesthetized and 
sacrificed to allow isolation of femoral muscle. 
Blood samples assays in mice. Serum levels of Lect2 were measured by Ab-Match 
ASSEMBLY Mouse LECT2 kit (MBL). Serum levels of insulin were determined using a 
mouse insulin ELISA kit (Morinaga Institute of Biological Science, Inc., Yokohama, Japan), 
according to the manufacturers’ instructions.  
Adenovirus-mediated gene transfer in H4IIEC hepatocytes. H4IIEC hepatocytes were 
grown to 90% confluence in 24-well multi-plates. Cells were infected with adenoviruses 
encoding dominant negative α1 and α2 AMPK, constitutively-active AMPK, or LacZ for 4 h 
(8.9 X 106 PFU/well) (31). We expressed α1 and α2 dominant negative AMPK 
simultaneously to maximize the effect on AMPK activity. After removing the adenoviruses, 
the cells were incubated with DMEM for 24 h. Then, RNA was isolated from the cells by 
using GenElute™ Mammalian Total RNA Miniprep Kit (Sigma Aldrich). 
Indirect calorimetry. Mice were housed in standard metabolic cages for 24 h. An indirect 
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calorimetry system (Oxymax Equal Flow System, Columbus Instruments, Columbus, U.S.A.) 
was used, in conjunction with the computer-assisted data acquisition program Chart5.2 (AD 
Instruments, Sydney, Australia), to measure and record oxygen consumption and carbon 
dioxide production at 5-min intervals. Heat generation was calculated per weight (kcal/kg/h). 
Measurement of hepatic triglyceride content in mice. 
Frozen liver tissue was homogenized in 2 ml ice-cold isopropanol after weight measurement. 
After 10min incubation with shaking at room temperature, the samples were centrifuged at 
3000 rpm for 10 min and supernatant 1 ml was transferred. Triglyceride content in each 
sample was measured by using commercial Triglyceride E-test WAKO kit (Wako Pure 
Chemical Industries, Osaka, Japan). Results were normalized to weight of each liver sample.  
Statistical analyses. All data were analyzed using the Japanese Windows Edition of the 
Statistical Package for Social Science (SPSS) Version 21.0. Numeric values are reported as 
the mean ± SEM. Differences between two groups were assessed using unpaired two-tailed 
t-tests.  Data involving more than two groups were assessed by analysis of variance 
(ANOVA).  Glucose and insulin tolerance tests were examined using repeated measures 
ANOVA. 
RESULTS 
Identification of a hepatic secretory protein involved in obesity 
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To identify hepatokines involved in the pathophysiology observed in obesity, we performed 
liver biopsies in humans and conducted a comprehensive analysis of gene expression profile, 
as we previously described (12; 19; 32; 33). We obtained ultrasonography-guided 
percutaneous needle liver biopsies from 10 people with type 2 diabetes and seven normal 
subjects. We subjected them to DNA chip analysis to identify genes whose hepatic 
expression was significantly correlated with body mass index (BMI) (Table S1). As a result, 
we found a positive correlation between hepatic LECT2 messenger RNA (mRNA) levels and 
BMI, indicating that elevated hepatic LECT2 mRNA levels were associated with obesity. 
Circulating LECT2 levels correlate with adiposity and insulin resistance in humans. 
To characterize the role of LECT2 in humans, we measured serum LECT2 levels in 
participants who visited the hospital for a complete physical examination. (Table S2), using 
enzyme-linked immunosorbent assays (26; 27). We found a significant positive correlation 
between serum LECT2 levels and BMI and waist circumference (Fig. 1A and 1B). LECT2 
levels also showed a significant correlation with the homeostasis model assessment of insulin 
resistance (HOMA-R) positively and with insulin sensitivity indices (Matsuda index) 
negatively (Fig. 1C and 1D). In addition, serum levels of LECT2 positively correlated with 
those of selenoprotein P, an already-reported hepatokine that induces insulin resistance (Fig. 
1E) (12). Moreover, LECT2 showed a correlation with levels of both hemoglobin A1c 
(HbA1c) and systolic blood pressure (Fig. 1F and 1G), both of which were reported to be 
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associated with insulin resistance (34; 35). These results indicate that serum levels of LECT2 
are positively associated with both adiposity and the severity of insulin resistance in humans.  
AMPK negatively regulates LECT2 expression in hepatocytes 
To confirm the elevation of LECT2 in animal models with obesity, we fed C57BL6J mice 
with a high fat diet (HFD) for 8 weeks (Fig. 2A-2F). HFD increased body weight 
time-dependently (Fig. 2A), and tended to increase triglyceride contents in the liver (Fig. 2B). 
Hematoxylin and Eosin staining showed mild steatosis in the mice fed HFD (Fig.2C). Gene 
expression for Lect2 was elevated in the livers of the mice fed HFD, in accordance with the 
steatosis-associated genes such as Fasn and Srebp1c (Fig. 2D). Serum levels of LECT2 
showed a sustained increase since a week after the beginning of HFD (Fig. 2E). Additionally, 
we confirmed that HFD even for a week resulted in an increase of serum levels of insulin and 
a decrease of insulin-stimulated Akt phosphorylation in the skeletal muscle in C57BL6J mice 
(Supplementary Fig. 1). Importantly, the livers from mice fed a HFD for 8 weeks showed a 
decrease of phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) 
(Fig. 2F), the energy-depletion-sensing kinase that phosphorylates a variety of 
energy-associated enzymes and functions as a metabolic regulator that promotes insulin 
sensitivity (36). Since a HFD for a short period increased LECT2 concentrations, we then 
examined the effects of feeding on blood LECT2 levels. LECT2 levels were elevated in 
blood obtained from fed C57BL6J mice, compared with samples from the fasting mice (Fig. 
16 
2G). Moreover, AMPK phosphorylation decreased in the livers from the mice that had been 
fed (Fig. 2H). Since LECT2 expression was inversely correlated with AMPK 
phosphorylation in the liver, we hypothesized that AMPK negatively regulates LECT2 
production in the hepatocytes. Exercise is reported to increase phosphorylation and activity of 
AMPK not only in the skeletal muscle but also in the liver in relation to the intrahepatic 
elevation of AMP levels (37; 38). Thus, we examined the actions of aerobic exercise on 
LECT2 expression in the liver. C57BL6J mice were loaded onto a running treadmill for a 
total of 3 h. Exercise decreased levels of gene expression and protein for LECT2 in the liver 
(Fig. 2I and 2J). Aerobic exercise for 3 h, but not resting, significantly reduced serum levels 
of LECT2 (Fig. 2K). Percent changes from baseline showed that the reduction of serum 
LECT2 in the exercise group was significantly larger than that in the rest group (FIG. 2K). In 
addition, aerobic exercise increased AMPK phosphorylation in the liver (Fig. 2L). To 
determine whether AMPK suppresses LECT2 expression, we transfected H4IIEC hepatocytes 
with adenoviruses either encoding constitutively active (CA-) or dominant-negative (DN-) 
AMPK. First, we found that transfection with CA-AMPK significantly decreased mRNA 
levels for Lect2 in H4IIEC hepatocytes, similarly to those for G6Pc that encodes key 
gluconeogenic enzyme glucose-6 phosphatase already-known to be suppressed by AMPK 
(39) (Fig. 2M). In contrast, transfection with DN-AMPK increased Lect2 gene expression 
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(Fig. 2N). These results indicate that AMPK negatively regulates LECT2 production in the 
hepatocytes. 
Lect2 deletion increases muscle insulin sensitivity in mice 
Next, we examined the role of LECT2 in the development of insulin resistance in mice. We 
found that gene expression for Lect2 in the liver was overwhelmingly dominant compared 
with that in the other tissues in mice (Fig. 3A). This result suggests that the contribution of 
the other tissues except the liver on the circulating levels of LECT2 is very small or 
negligible in mice. Hence, we used systemic knockout mice of LECT2 in the following 
experiments, although the animal models of liver-specific down-regulation for LECT2 might 
be more suitable. We confirmed that serum LECT2 was undetectable in Lect2-deficient mice 
by using ELISA (Fig. 3B). Body weight, food intake, and resting heat production were 
unaffected by Lect2 knockout (Fig. 3C-3E). However, the treadmill running challenge 
revealed that physical-exercise-assessed muscle endurance was significantly higher in Lect2–
/– mice (Fig. 3F and 3G). A glucose or insulin loading test revealed that Lect2–/– mice showed 
lower blood glucose levels after glucose or insulin injection (Fig. 3H and 3I). Lect2–/– mice 
exhibited an increase in insulin-stimulated Akt phosphorylation in skeletal muscle (Fig. 3J 
and 3K), but not in the liver or adipose tissue (Supplementary Fig. 2A and 2B). Furthermore, 
JNK phosphorylation was unchanged in the liver and adipose tissue of these knockout mice 
(Supplementary Fig. 2C and 2D). Consistent with the results of insulin signaling, 
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hyperinsulinemic-euglycemic clamp studies showed that the glucose infusion rate and 
peripheral glucose disposal were increased, whereas endogenous glucose production was 
unaffected by Lect2 deletion (Fig. 3L, and Supplementary Fig. 3). In addition, expression of 
the genes involved in mitochondria and myogenesis such as UCP3, Myh1, Myh2, and Ppard, 
were upregulated in the muscle of Lect2–/– mice (Fig. 3M). These results indicate that a Lect2 
deletion increases insulin sensitivity in the skeletal muscle in mice. 
Lect2 deletion attenuates muscle insulin resistance in dietary obese mice 
To further elucidate the role of LECT2 in the development of obesity-associated insulin 
resistance, we fed Lect2-deficient mice a HFD. HFD-induced body weight gain was smaller 
in Lect2-deficient mice compared with wild-type animals (Fig. 4A). To examine the 
mechanism by which Lect2-deficient mice were less obese following HFD feeding, we 
measured food intake and heat production in Lect2-deficient mice fed a HFD for only a week, 
when the body weight was comparable between the wild-type and knockout mice 
(Supplementary Fig. 4A). Food intake was unaffected (Supplementary Fig. 4B), but heat 
production as measured by O2 consumption was significantly increased in Lect2-deficient 
mice fed HFD (Supplementary Fig. 4C) in both light and dark phases (Supplementary Fig. 
4D and 4E). 11 weeks later after HDF feeding, serum levels of insulin and blood levels of 
glucose decreased in these knockout mice (Fig. 4B and 4C). A glucose or insulin loading test 
revealed that Lect2-knockout mice showed lower blood glucose levels after glucose or insulin 
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injection (Fig. 4D and 4E). Consistent with the result of the insulin loading test, Western 
blotting revealed that insulin-stimulated Akt phosphorylation increased in skeletal muscle of 
these knockout animals (Fig. 4F and 4G). In contrast, JNK phosphorylation significantly 
decreased in skeletal muscle of Lect2-deficient mice (Fig. 4H and 4I). Furthermore, we 
examined muscle insulin signaling in Lect2-deficient mice fed a HFD for only 2 weeks, when 
the body weight was comparable between wild-type and the knockout mice (Supplementary 
Fig. 5A, 5B, and 5C). Insulin-stimulated Akt phosphorylation was significantly increased in 
the muscle of Lect2-deficient mice under conditions of HFD for 2 weeks (Supplementary Fig. 
5D and 5E). These results indicate that Lect2 deletion reduces muscle insulin resistance in 
dietary obese mice.  
Starvation abolishes the insulin sensitive phenotype in Lect2-deficient mice 
Next, to elucidate the role of LECT2 in a condition of severe undernutrition, we starved 
Lect2-deficient mice for 60 hours. Starvation decreased body weight and blood glucose levels 
time-dependently, whereas there was no significance between wild-type and Lect2-deficient 
mice (Fig. 5A and 5B). Consistent with the changes of body weight, serum levels of LECT2 
in wild-type animals significantly decreased during the starvation (Fig. 5C). Before the 
starvation, serum levels of insulin in LECT2 knockout mice were lower compared with 
wild-type mice (Fig. 5D). However, the starvation reduced insulin levels to the extent to 
which the difference abolished between the two groups (Fig. 5D). Insulin-stimulated Akt 
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phosphorylation in the skeletal muscle also showed no difference between the two groups 
after the starvation for 60 hours (Fig. 5E). These results indicate that starvation abolishes the 
insulin-sensitive phenotype in Lect2-deficient mice.  
LECT2 impairs insulin signaling by activating JNK in C2C12 myotubes 
Firstly, to examine the effect of LECT2 on insulin signaling in vitro, we transfected C2C12 
myocytes with a plasmid expression vector encoding mouse LECT2. Expression of 
endogenous LECT2 was negligible in C2C12 myocytes transfected with a negative control 
vector (Fig. 6A and 6B). We confirmed that C2C12 myotubes transfected with the LECT2 
expression vector expressed Lect2 mRNA and released LECT2 protein into culture medium 
(Fig. 6A and 6B). LECT2 transfection suppressed myotube differentiation in C2C12 cells 
(Fig. 6C). The cells transfected with the LECT2 vector showed a decrease in 
insulin-stimulated Akt phosphorylation (Fig. 6D) and an increase in basal c-Jun-N-terminal 
kinase (JNK) phosphorylation (Fig. 6E). 
To further confirm the acute action of LECT2 on insulin signaling, we treated C2C12 
myotubes with recombinant LECT2 protein at nearly physiological concentrations. Treatment 
with 400 ng/ml of LECT2 protein for 3 h decreased insulin-stimulated Akt phosphorylation 
(Fig. 6F). In addition, treatment with LECT2 protein for 30-60 min increased JNK 
phosphorylation transiently in C2C12 myotubes (Fig. 6G). LECT2-induced JNK 
phosphorylation was observed to occur in a concentration-dependent manner (Fig. 6H). To 
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determine whether JNK pathway mediates LECT2-induced insulin resistance, we transfected 
C2C12 myoblasts with siRNAs specific for JNK1 and JNK2. Because knockdown of JNK is 
known to alter the myotube-differentiation in C2C12 myotubes (40), we used undifferentiated 
C2C12 myoblasts to purely assess the action of LECT2 on insulin signal transduction in the 
following experiments. Double knockdown of JNK1 and JNK2 rescued the cells from the 
inhibitory effects of LECT2 on insulin signaling (Fig. 6I). Inflammatory signals and 
endoplasmic reticulum stress are known to be the powerful inducers of JNK (41). However, 
the markers of neither inflammation nor endoplasmic reticulum stress were changed in 
C2C12 myotubes overexpressed with LECT2 and in the skeletal muscle of LECT2 knockout 
mice (Supplementary FIG. 4). These in vitro experiments indicate that, at nearly 




Our research reveals that the overproduction of hepatokine LECT2 contributes to the 
development of muscle insulin resistance in obesity (Fig. 7). Recently, growing evidence 
suggests a central role for fatty liver disease in the development of insulin resistance in 
obesity (4; 42). Kotronen et al. have reported that intrahepatocellular rather than 
intramyocellular fat associates with hyperinsulinemia independently of obesity in 
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non-diabetic men (43). Fabbrini et al. have revealed that intrahepatic triglyceride, but not 
visceral adipose tissue, is a better marker of multiorgan insulin resistance associated with 
obesity (44). D’Adamo et al. have shown that obese adolescents with high hepatic fat content 
show lower whole-body insulin sensitivity independently of visceral fat and intramyocellular 
lipid content (45). These papers indicate a strong correlation between fatty liver and muscle 
insulin resistance in humans, but it was still unknown whether fatty liver disease directly 
causes muscle insulin resistance in obesity. The liver is a major site for the production of 
bioactive secretory proteins, termed hepatokines (12; 19). Many lines of evidence have 
reported that the dysregulation of hepatokine production such as selenoprotein P or fetuin A 
is involved in the development of systemic insulin resistance (12; 13; 46; 47). The current 
study demonstrates a previously-unrecognized role for LECT2 in glucose metabolism and 
suggests that LECT2 is a strong candidate to explain a mechanism by which the fatty liver 
leads to whole-body insulin resistance in obesity. 
The energy-depletion-sensing kinase AMPK functions as a metabolic sensor that promotes 
insulin sensitivity (36). Exercise is known to increase phosphorylation and activity of AMPK 
in skeletal muscle. Early reports have shown that exercise-induced AMPK phosphorylation is 
also observed in the liver (37; 38). On the other hand, a high fat diet is reported to decrease 
AMPK phosphorylation in the liver, probably due to excessive accumulation of energy (48; 
49). Negative regulation of LECT2 by energy-depletion-sensing kinase AMPK supports the 
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concept that LECT2 functions as an over-nutrition-sensing hepatokine. One limitation of this 
study is that the molecular mechanism by which AMPK reduces LECT2 expression is still 
unknown. Additional studies are needed to determine the transcriptional factors that 
negatively regulate LECT2 expression downstream of AMPK pathway.  
JNK is a mitogen-activated protein kinase that is activated by various stimuli, including 
cytokines, reactive oxygen species, endoplasmic reticulum stress, and metabolic changes (41). 
JNK plays a major role in the development of insulin resistance induced by high fat diet, by 
phosphorylating insulin receptor substrates at specific serine and threonine residues (50; 51). 
More recently, several studies suggest a role for JNK in the development of insulin resistance 
in skeletal muscle, as well as in the liver or adipose tissue. Ferreira et al. reported an increase 
of JNK phosphorylation and a decrease of insulin-stimulated Akt phosphorylation in the 
skeletal muscle from patients with non-alcoholic steatohepatitis (52). Henstridge et al. 
showed that muscle-specific overproduction of constitutively active JNK induces muscle 
insulin resistance in mice (53). Conversely, Sabio et al. revealed that muscle-specific JNK 
knockout mice exhibit improved insulin sensitivity in skeletal muscle (54). Hence, 
overproduction of LECT2 in the liver may contribute, at least partly, to JNK phosphorylation 
and the subsequent insulin resistance observed in the skeletal muscle of patients with obesity. 
However, the mechanism by which LECT2 increases JNK phosphorylation remains 
unresolved. Our results suggest that LECT2-induced JNK activation in cultured myocytes is 
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independent of inflammation or endoplasmic reticulum stress (Supplementary Fig. 4). 
Identification of the LECT2 receptor and characterization of its downstream signaling will 
provide insights into the involvement of LECT2 in JNK phosphorylation. 
We show that overexpression of LECT2 does not alter the inflammatory response in 
cultured myotubes. Early reports suggest that LECT2 exerts different effects on inflammation 
depending on various pathological conditions. Inflammation observed in autoimmune 
disorders such as collagen antibody-induced arthritis or concanavalin A-induced hepatitis is 
reported to be suppressed by LECT2 (17; 55). LECT2 also attenuates β-catenin-induced 
inflammation associated with hepatocellular carcinoma in mouse models (18). On the other 
hand, a more recent report showed that LECT2 activates lipopolysaccharide-stimulated 
macrophages via the CD209a receptor, resulting in an improvement of survival prognosis in 
mice with bacterial sepsis (56). Because we found no gene expression levels of CD209a in 
C2C12 myotubes in Realtime PCR experiments (data not shown), LECT2-induced insulin 
resistance in cultured myocytes is likely to be independent of inflammatory response via the 
CD209a receptor. However, it is unknown whether LECT2 affects macrophages observed in 
the adipose tissue of obesity. The actions of LECT2 on low grade inflammation seen in 
obesity are now under investigation. 
Interestingly, although LECT2 knockout mice showed an increase of insulin signaling in the 
skeletal muscle when fed HFD or regular chow, this increase was abolished after starvation 
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for 60 hours. Serum levels of LECT2 were increased by HFD (FIG. 2E), whereas they were 
decreased by starvation in wild-type mice (FIG. 5C). Hence, it seems most likely that the 
difference in serum LECT2 levels between wild-type and the knockout mice was enhanced 
by HFD, whereas it was reduced by starvation. The abolishment of the insulin-sensitive 
phenotypes in LECT2 knockout mice after starvation may be explained by reduction of the 
difference in serum LECT2 levels. These results suggest that LECT2 plays a major role in the 
regulation of insulin sensitivity in the over-nutritional conditions, but not in the 
under-nutritional ones. 
Our data reveal that 60% HFD for 1 week resulted in a decrease of insulin signaling of the 
skeletal muscle and an increase of circulating levels of LECT2 in C57BL6 mice concurrently. 
A previous clinical report showed that overfeeding and inactivity for only 3 days impaired 
insulin sensitivity in healthy young men (57). Impairment of insulin sensitivity occurred 
before changes in body composition such as total fat mass and visceral fat area. However, 
additional clinical studies are required to determine whether high fat diet for several days 
indeed induces simultaneous alterations of circulating LECT2 and muscle insulin sensitivity 
in humans.  
C2C12 myocytes transfected with pLect2 showed an impairment of myotube differentiation 
and insulin signal transduction (FIG. 6C and 6D). The presence of LECT2 protein in the 
culture medium (FIG. 6B) suggests that LECT2 derived from the pLect2 acted on the cells in 
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an autocrine or paracrine manner. Because the half-life of LECT2 protein was predicted to be 
short due to the low molecular weight of LECT2 (16 kDa), we initially overexpressed LECT2 
in the cultured myocytes to examine the chronic actions of LECT2. In the next experiments, 
we directly treated well-differentiated C2C12 myoblasts with recombinant LECT2 protein for 
3 hrs (FIG. 6F) to exclude the possibility that LECT2-induced suppression of myotube 
differentiation secondarily causes insulin resistance in pLect2 experiments. The results 
obtained from the experiments using the recombinant LECT2 protein suggest that LECT2 
directly induces insulin resistance in C2C12 cells independently of its action on myotube 
differentiation. 
Okumura et al. reported that treatment with LECT2 ameliorated collagen antibody-induced 
arthritis in mice (55). This report suggests that LECT2 suppresses the inflammatory response 
that progresses after the development of autoantibodies. Several clinical studies showed that 
the onset of inflammatory polyarthritis such as Rheumatoid arthritis is accelerated by obesity 
(58; 59). Because our current data reveal the positive correlation between body mass index 
and serum LECT2 levels in humans, it appears that overproduction of LECT2 fails to exert 
sufficient suppressive action on inflammatory polyarthritis in people with obesity. However, 
it is still unknown whether LECT2 acts on the process of autoantibody production by B 
lymphocytes in the acquired immune system. Further basic and clinical studies are needed to 
investigate the relationship between LECT2 and obesity-associated arthritis. 
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Our current cross-sectional data show that serum levels of LECT2 positively correlate with 
the severity of insulin resistance in human subjects. However, many lines of evidence 
demonstrated that various circulating proteins whose expression is altered in obesity, such as 
adiponectin and resistin, participate in the development of insulin resistance (60). Hence, our 
study does not necessarily place LECT2 as only a single causal factor of insulin resistance. 
Additionally, further prospective studies are needed to confirm the causal relationship 
between LECT2 and insulin resistance in people with obesity. 
In summary, our experiments have identified LECT2 as an obesity-upregulated hepatokine 
that induces skeletal muscle insulin resistance. LECT2 may be a potential target for the 
treatment of obesity-associated insulin resistance. 
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 Figure legends 
FIG.1. Circulating LECT2 correlates with adiposity and insulin resistance. A-F: 
Individual correlations between serum levels of LECT2 and body mass index (A) waist 
circumference (B), HOMA R index (C), insulin sensitivity (Matsuda index) (D), 
selenoprotein P (SeP) (E), HbA1c (F), and systolic blood pressure (G) in humans (n = 200).  
FIG.2. AMPK negatively regulates Lect2 expression in the liver. A: Body weight of 
C57BL6J mice fed a high fat diet (HFD; n = 15) or regular diet (RD; n = 16). Five-week-old 
male mice were fed a HFD for 8 weeks. B: Triglyceride contents in the livers of C57BL6J 
mice fed a HFD or a RD for 8 weeks (n = 7-8). C: Hematoxylin and Eosin staining of livers 
from C57BL6J mice fed a HFD or a RD for 8 weeks. D: mRNA levels for Lect2, Fasn, and 
Srebp1c in the livers of C57BL6J mice fed a HFD or a RD for 8 weeks (n = 7-8). E: Changes 
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of blood levels of LECT2 in C57BL6J mice fed HFD (n = 8) or RD (n = 8). Blood samples 
were obtained after fasting for 12 hr. F: Phosphorylation of AMPK in the livers of C57BL6J 
mice fed a HFD or a RD after a 12-h fast (n = 4). G: Blood levels of LECT2 from C57BL6J 
mice following fasting for 12 h and subsequent feeding for 12 h (n = 7-8). H: 
Phosphorylation of AMPK in the livers of C57BL6J mice following fasting for 12 h and 
subsequent feeding for 12 h (n = 3). I: mRNA levels for Lect2 in the livers of C57BL6J mice 
following running exercise for 3 h (n = 7-8). J: Protein levels of LECT2 in the livers of 
C57BL6J mice following running exercise for 3 h (n = 7-8). K: Serum levels of LECT2 in 
C57BL6J mice before and after running exercise for 3 h (n = 8, Paired t-test). Right panel: 
Percentage changes of serum LECT2 after running exercise for 3h (unpaired t-test). L: 
Phosphorylation of AMPK in the livers of C57BL6J mice following running exercise for 3 h 
(n = 3-4). M: Effects of constitutively active (CA-) AMPK on mRNA levels for Lect2 and 
G6pc in H4IIEC hepatocytes (n = 4). N: Effects of dominant-negative (DN-) AMPK on 
mRNA levels for Lect2 and G6pc in H4IIEC hepatocytes (n = 4). 
Data in (A-B), and (D-N) represent the means ± SEM. *P < 0.05, **P< 0.01, ***P < 0.001. 
Fasn, fatty acid synthase; Srebp1c, sterol regulatory-element binding protein-1c; G6pc, 
glucose-6 phosphatase.  
FIG.3. Lect2 deletion increases muscle insulin sensitivity in mice. A: Lect2 mRNA levels 
in various tissues of C57BL6J mice (n = 4-8). B: Serum levels of LECT2 in Lect2-deficient 
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and wild-type mice fed a HFD for 10 weeks (n = 9-13). Blood samples were obtained in fed 
condition. C: Body weight of Lect2-deficient and wild-type mice fed a regular diet (n = 6-8). 
D: Food intake of Lect2-deficient and wild-type mice (n = 6-8). E: Heat production of 
Lect2-deficient and wild-type mice (n = 6-8). F and G: Running endurance was tested in 
Lect2-deficient and wild-type mice (n = 7-8). Running endurance is depicted as distance (F) 
and time (G). H and I: Intraperitoneal glucose (H) and insulin (I) tolerance tests in 
Lect2-deficient and wild-type mice (n = 7-8). Glucose and insulin were administered at doses 
of 2.0 g/kg body weight and 1.0 units/kg body weight, respectively. J and K: Western blot 
analysis and quantification of phosphorylated Akt in skeletal muscle of Lect2-deficient and 
wild-type mice (n = 5). 19-week-old female mice were stimulated with insulin (administered 
through vena cava) at doses of 1 unit/kg body weight. At 10 min after insulin administration, 
the hind-limb muscles were removed. L: Glucose infusion rate (GIR), endogenous glucose 
production (EGP), and rate of glucose disposal (Rd) during hyperinsulinemic-euglycemic 
clamp in Lect2-deficient and wild-type mice (n = 6-7). M: mRNA levels of genes involved in 
myogenesis and mitochondria in skeletal muscle of Lect2-deficient and wild-type mice (n = 
4-5). 
 Data in (A-I), and (K-M), represent the means ± SEM. *P < 0.05, **P < 0.01, ***P< 0.001 




 FIG. 4. Lect2 deletion attenuates muscle insulin resistance in diet-induced obesity in 
mice. A: Changes of bodyweight of Lect2-deficient mice and wild-type mice fed with high fat 
diet (HFD; n = 9-13). B: Serum insulin levels of Lect2-deficient and wild-type mice fed with 
HFD for 11 weeks in a fed condition and after 12 hours fasting. (n = 9-13). C: Blood glucose 
levels of Lect2-deficient and wild-type mice fed with HFD for 11 weeks in a fed condition 
and after 12 hours fasting. (n = 9-13). D: Intraperitoneal glucose tolerance tests in 
Lect2-deficient and wild-type mice fed with HFD for 9 weeks (n = 9-13). Glucose was 
administered at doses of 0.5 g/kg body weight. E: Intraperitoneal insulin tolerance tests in 
Lect2-deficient and wild-type mice fed with HFD for 10 weeks (n = 9-13). Insulin was 
administered at doses 1.2 units/kg body weight. F-G: Western blot analysis and quantification 
of phosphorylated Akt in skeletal muscle of Lect2-deficient and wild-type mice (n = 3-4). 
H-I: Western blot analysis and quantification of phosphorylated JNK in skeletal muscle of 
Lect2-deficient and wild-type mice (n = 3-4). Mice were stimulated with insulin 
(administered through vena cava) at doses of 1 unit/kg body weight. At 2 min after insulin 
administration, the hind-limb muscles were removed.  
 Data in (A-E) and (G) represent the means ± SEM. *P < 0.05, **P < 0.01, ***P< 0.001 
(Lect2-deficient mice versus wild-type mice) 
FIG. 5. Starvation abolishes the insulin sensitive phenotype in Lect2-deficient mice.  
A: Body weight of female Lect2-deficient and wild-type mice (n = 5) during starvation at the 
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age of 20 weeks. B: Blood glucose levels of Lect2-deficient and wild-type mice (n = 5) 
during starvation. C: Serum levels of insulin of Lect2-deficient and wild-type mice (n = 4-5) 
in a fed condition or after starvation for 36 hours (paired t-test). D: Serum levels of LECT2 of 
wild-type mice (n = 4-5) in a fed condition or after starvation for 36 hours. E: Western blot 
analysis of phosphorylated Akt in skeletal muscle of Lect2-deficient and wild-type mice after 
60 hours starvation. Mice were stimulated with insulin (administered intraperitoneally). At 15 
min after insulin administration, mice were anesthetized and hind-limb muscle samples were 
removed for analysis. 
Data in (A-D) represent the means ± SEM. Data in (D) were assessed by paired t-tests. *P < 
0.05. 
FIG. 6. LECT2 impairs insulin signaling by activating JNK in C2C12 myotubes. 
C2C12 myoblasts in 30-50% confluency were transfected with negative control or mLect2 
expression plasmid in (A)-(E). When the cells reached to 100% confluency, the cells were 
differentiated into myotubes with DMEM containing 2% horse serum for 24-48 h. A: Lect2 
mRNA levels in C2C12 myotubes transfected with control or Lect2 expression vector (n = 6). 
mRNA was obtained from the cells differentiated into myotubes for 24 h. B: LECT2 protein 
levels in culture medium of C2C12 myotubes transfected with control or Lect2 expression 
vector for 24h or 72h (n = 3). LECT2 production was measured in by ELISA. C: 
Representative images of C2C12 myotubes transfected with control or Lect2 expression 
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vector. The cells were differentiated into myotubes for 48 h. D: Western blot analysis of 
phosphorylated Akt in C2C12 myotubes transfected with control or Lect2 expression vector 
(n = 4). The cells were stimulated by 100 ng/ml of insulin for 15 min. E: Western blot 
analysis of phosphorylated JNK in C2C12 myotubes transfected with control or Lect2 
expression vector (n = 3). F: Western blot analysis of phosphorylated Akt in C2C12 myotubes 
pretreated with recombinant LECT2 protein (n = 4). The cells were pretreated with LECT2 
protein. Three hours later, the cells were stimulated with insulin. G: Effects of recombinant 
LECT2 protein on JNK phosphorylation in C2C12 myotubes (n = 3). The cells were treated 
with 400 ng/ml of recombinant LECT2 protein for the indicated times. H: 
Concentration-dependent effects of recombinant LECT2 protein on JNK phosphorylation in 
C2C12 myotubes (n = 3). The cells were treated with LECT2 protein for 1 h. I: Effects of 
JNK-knockdown on LECT2 protein-induced insulin resistance in C2C12 myoblasts (n = 4).  
Data in (A), (B) and (D-I) represent the means ± SEM. *P < 0.05, **P < 0.01, ***P< 0.001 
versus cells transfected with control vector or cells treated with vehicle.  






 Table S1, relative to Fig. 1. Candidate hepatokine genes involved in obesity. 
Unigene Symbol Name 
DM/NGT, 
by SAGE 

















0.15 0.0020 0.54 
Hs.443518 BPAG1 
Homo sapiens dystonin
 (DST), transcript vari
ant leA, mRNA 




serine (or cysteine) 
proteinase inhibitor, 
clade F (alpha-2 
antiplasmin, pigment 
epithelium derived 
factor), member 1 
2.02 0.01 0.47 
Hs.157307 GNAS 
GNAS complex locus 
1.99 0.01 0.47 
Hs.324746 AHSG 
AHSG alpha2 HS 
glycoprotein 
0.02 0.02 0.42 
Hs.10458 CCL 16 
chemokine (C-C motif) 
ligand 16 
6.82 0.02 0.42 
Hs.168718 AFM 
afamin 




factor beta binding 
protein 1 
0.05 0.02 0.42 
Hs.1012 C4BPA 
complement component 
4 binding protein, alpha 




0.45 0.03 0.4 




0.05 0.03 0.4 
Hs.4 06455 PSAP 
prosaposin (variant 
Gaucher disease and 
variant metachromatic 
leukodystrophy) 
2.47 0.03 0.4 
Hs. 1498 ERG 
histidine-rich 
glycoprotein 
8.49 0.04 0.39 
Hs.9914 FST 
FST follistatin 
0.02 0.04 0.38 
Hs.119651 GPC3 
glypican 3 





2.27 0.04 0.38 
Hs.75615 APOC2 
Apolipoprotein C-II 
2.02 0.04 0.37 
Hs.515258 GDF15 
GDF15 growth 
differentiation factor 15 
0.03 0.04 0.37 
Hs. 31439 SPINT2 
SPINT2 serine protease 
inhibitor Kunitz type 2 





necrosis factor receptor 
superfamily member 1A 
0.05 0.05 0.36 
 
BMI, body mass index. 
   
Table S2, relative to Fig.1. Clinical characteristics of the human subjects whose blood 
was sampled.  
  
N 200 
Age (years) 55±11 
Sex (M/F) 118/82 
Body mass index (kg/m2) 22.9±3.1 
Waist circumstance (cm) 81.0±9.0 
Fasting plasma glucose (mg/dl) 97±11 
HOMA-IR 1.4±0.9 
HbA1c (%) 5.7±0.4 
Systolic blood pressure (mmHg) 124±18 
Selenoprotein P (µg/ml) 6.0±0.8 
 
HOMA-IR, homeostasis model assessment for insulin resistance; HbA1c, hemoglobin A1c.  
Blood was sampled following overnight fasting.   
  
Supplementary Figure 1. Insulin resistance in mice fed a 60% high fat diet for 1 week. 
(A) Body weight of C57BL6J mice fed a high fat diet (HFD; n = 8) or regular diet (RD; n = 
8). Five-week-old male mice were fed a HFD for 1 week. (B) Blood glucose levels of 
C57BL6J mice fed a HFD or a RD for 1 week (n = 8). (C) Serum levels of insulin in 
C57BL6J mice fed a HFD or a RD for 1 week (n = 8). (D) Serum levels of LECT2 in 
C57BL6J mice fed HFD (n = 8) or RD (n = 8). (E) and (F) Western blot analysis and 
quantification of the bands of phosphorylated Akt in skeletal muscle of C57BL6J mice fed a 
HFD or a RD after a 12-h fast (n = 3). Mice were injected with insulin intraperitoneally (10 
units/kg body weight). At 15 min after insulin administration, mice were anesthetized and 
hind-limb muscle samples were removed for analysis. Data in (A-D) and (F) represent the 





Supplementary Figure 2. Insulin signalling and JNK phosphorylation in the liver and 
adipose tissue of Lect2-deficinet and wild-type mice. (A) and (B) Western blot analysis of 
phosphorylated Akt in liver and white adipose tissue of Lect2-deficient and wild-type mice. 
Mice were stimulated with insulin intraperitoneally (10 units/kg body weight). At 15 min 
after insulin administration, mice were sacrificed and liver and epididymal white adipose 
tissue samples were removed for analysis. (C) and (D) Western blot analysis of 
phosphorylated JNK in liver and white adipose tissue of Lect2-deficient and wild-type mice 





Supplementary Figure 3. Glucose levels during hyperinsulinemic-euglycemic clamp. (A)
Time course of blood glucose levels during hyperinsulinemic-euglycemic clamp in wild-type 
and Lect2-deficient mice (n = 6-7). (B) Time course of glucose infusion rate during 
hyperinsulinemic-euglycemic clamp in wild-type and Lect2-deficient mice (n = 6-7). (C)
Average of blood glucose levels at the last 30 min (90min, 105min and 120min) in wild-type 
and Lect2-deficient mice (n = 6-7). Data in (A)- (C) represent the means ± SEM. *P < 0.05 
versus the wild-type mice.
Supplementary Figure 4. Food intake and heat production in wild-type and Lect2-deficient 
mice fed a HFD for a week (A) Body weight of Lect2-deficient and wild-type mice fed a 
HFD for a week (n = 7-8). (B) Food intake of of Lect2-deficient and wild-type mice fed a 
HFD for a week (n = 7-8). (C) Heat production of of Lect2-deficient and wild-type mice fed a 
HFD for a week (n = 7-8). (D) Heat production in light phase of Lect2-deficient and 
wild-type mice fed a HFD for a week (n = 7-8). (E) Heat production in light phase of 
Lect2-deficient and wild-type mice fed a HFD for a week (n = 7-8). Data represent the means 





Supplementary Figure 5. Lect2 deletion increases muscle insulin sensitivity in mice fed a 
HFD for 2 weeks. (A) Changes of bodyweight of 22 weeks-old Lect2-deficient and wild-type 
mice fed a HFD for 2 weeks (n=7). (B) The bodyweight of 22 weeks-old Lect2-defeicient and 
wild-type mice before sacrifice. (n=7). (C) The weight of left epididymal adipose tissue of 
Lect2-deficient and wild-type mice (n=7). (D) Western blot analysis of phosphorylated Akt in 
skeletal muscle of Lect2-deficient and wild-type mice. Mice were stimulated with insulin 
(administered through vena cava) at doses of 1 units/kg body weight. At 10 min after insulin 
administration, hind-limb muscles were removed. (E) Quantification of phosphorylated Akt 






Supplementary Figure 6. Markers of ER stress or inflammation in C2C12 myocytes 
transfected with pLect2 or in the muscles of Lect2-deficient mice. (A) CHOP mRNA levels 
in skeletal muscle of Lect2-deficient and wild-type mice fed with normal chow (n = 8-9). (B) 
CHOP mRNA levels in C2C12 myotubes transfected with control or Lect2 expression vector 
(n = 6), mRNA was obtained from the cells differentiated into myotubes for 48 h. (C) 
Western blot analysis of BiP in in skeletal muscle of Lect2-deficient and wild-type mice fed 
with 60% high fat diet for 15 weeks. (D) Western blot analysis of p-eIF2α in C2C12 
myotubes transfected with control or Lect2 expression vector. (E) Tnf-α mRNA levels in 
skeletal muscle of Lect2-deficient and wild-type mice fed a regular diet (n = 7-8). (F) Tnf-α 
mRNA levels in C2C12 myotubes transfected with control or Lect2 expression vector (n = 6). 
mRNA was obtained from the cells differentiated into myotubes for 2 days. (G) Western blot 
analysis of inflammation-associated proteins in C2C12 myotubes transfected with control or 
Lect2 expression vector. Data in (A-B) and (E-F) represent the means ± SEM. 
CHOP, CCAAT/-enhancer-binding protein homologous protein; BiP, Binding 
immunoglobulin protein; eIF2, Eukaryotic Initiation Factor 2; Tnfa, Tumor necrosis factor α; 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IKK, IκB kinase; 
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